1509 related articles for article (PubMed ID: 28110982)
21. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
22. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK
Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
[TBL] [Abstract][Full Text] [Related]
24. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
Urol Int; 2017; 99(4):384-391. PubMed ID: 28651247
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
26. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
Lovegrove CE; Miah S; El-Shater Bosaily A; Bott S; Brown L; Burns-Cox N; Dudderidge T; Freeman A; Henderson A; Hindley R; Kaplan R; Kirkham A; Oldroyd R; Parker C; Persad R; Punwani S; Rosario D; Shergill I; Winkler M; Emberton M; Ahmed HU
J Urol; 2020 Jan; 203(1):100-107. PubMed ID: 31335254
[TBL] [Abstract][Full Text] [Related]
28. A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol.
Kasivisvanathan V; Jichi F; Klotz L; Villers A; Taneja SS; Punwani S; Freeman A; Emberton M; Moore CM
BMJ Open; 2017 Oct; 7(10):e017863. PubMed ID: 29025845
[TBL] [Abstract][Full Text] [Related]
29. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
30. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.
Arsov C; Rabenalt R; Blondin D; Quentin M; Hiester A; Godehardt E; Gabbert HE; Becker N; Antoch G; Albers P; Schimmöller L
Eur Urol; 2015 Oct; 68(4):713-20. PubMed ID: 26116294
[TBL] [Abstract][Full Text] [Related]
31. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer.
Mozer P; Rouprêt M; Le Cossec C; Granger B; Comperat E; de Gorski A; Cussenot O; Renard-Penna R
BJU Int; 2015 Jan; 115(1):50-7. PubMed ID: 24552477
[TBL] [Abstract][Full Text] [Related]
32. Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.
Walton Diaz A; Shakir NA; George AK; Rais-Bahrami S; Turkbey B; Rothwax JT; Stamatakis L; Hong CW; Siddiqui MM; Okoro C; Raskolnikov D; Su D; Shih J; Han H; Parnes HL; Merino MJ; Simon RM; Wood BJ; Choyke PL; Pinto PA
Urol Oncol; 2015 May; 33(5):202.e1-202.e7. PubMed ID: 25754621
[TBL] [Abstract][Full Text] [Related]
33. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
34. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
[TBL] [Abstract][Full Text] [Related]
35. [Interest using 3D ultrasound and MRI fusion biopsy for prostate cancer detection].
Marien A; De Castro Abreu A; Gill I; Villers A; Ukimura O
Prog Urol; 2017 Sep; 27(10):521-528. PubMed ID: 28629785
[TBL] [Abstract][Full Text] [Related]
36. Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
Ullrich T; Arsov C; Quentin M; Mones F; Westphalen AC; Mally D; Hiester A; Albers P; Antoch G; Schimmöller L
Eur Radiol; 2020 Nov; 30(11):6042-6051. PubMed ID: 32591887
[TBL] [Abstract][Full Text] [Related]
37. Magnetic resonance imaging-guided biopsies may improve diagnosis in biopsy-naive men with suspicion of prostate cancer.
Winther MD; Balslev I; Boesen L; Logager V; Noergaard N; Thestrup KD; Thomsen HS
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552089
[TBL] [Abstract][Full Text] [Related]
38. [Focusing on MRI-suspected lesions in targeted transrectal prostate biopsy guided by MRI-TRUS fusion imaging for the diagnosis of prostate cancer].
Qu HW; Liu H; Cui ZL; Jin XB; Zhao Y; Wang MW; Song W; Zhang XJ
Zhonghua Nan Ke Xue; 2016 Sep; 22(9):782-786. PubMed ID: 29071873
[TBL] [Abstract][Full Text] [Related]
39. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.
Schoots IG; Roobol MJ; Nieboer D; Bangma CH; Steyerberg EW; Hunink MG
Eur Urol; 2015 Sep; 68(3):438-50. PubMed ID: 25480312
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.
Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Bladou F; Mercado A; Levental M; Ghai S; Chang SD; Milot L; Patel C; Kassam Z; Moore C; Kasivisvanathan V; Loblaw A; Kebabdjian M; Earle CC; Pond GR; Haider MA
JAMA Oncol; 2021 Apr; 7(4):534-542. PubMed ID: 33538782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
